Biogen (BIIB)
(Delayed Data from NSDQ)
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Zacks News
Biogen (BIIB) Stock Up This Year So Far on Aduhelm Approval
by Zacks Equity Research
Biogen's (BIIB) new Alzheimer's drug, Aduhelm should bring in huge revenues, if successfully commercialized.
Cassava (SAVA) Down as Quanterix Issues Statement on AD Study
by Zacks Equity Research
Cassava (SAVA) tanks yet again after Quanterix stated that it did not interpret the test results or prepare the data charts presented by the former.
Biogen Inc. (BIIB) Stock Moves -0.15%: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $342.24 in the latest trading session, marking a -0.15% move from the prior day.
Cassava (SAVA) Responds to Charges Against its Integrity in AD Study
by Zacks Equity Research
Cassava (SAVA) plunges following charges against its scientific integrity in developing a drug for Alzheimer's disease. The company responds to the same.
3 Big Drug/Biotech Outperformers Worth Keeping an Eye On (Revised)
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
3 Big Drug/Biotech Outperformers Worth Keeping an Eye On
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
Delta Variant Catches Up with the Stock Market
by Mark Vickery
Today, worries about growth and demand, at least partially caused by the Delta variant of Covid-19 manifesting in pockets of America.
Here is Why Prothena (PRTA) is Up More Than 155% in Three Months
by Zacks Equity Research
Prothena (PRTA) surges substantially in the past three months on solid prospects of its AD candidates following Biogen???s AD drug approval.
How Are Biotech ETFs Reacting to These Q2 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Ionis (IONS) Q2 Earnings & Revenues Fall Short of Estimates
by Zacks Equity Research
Ionis (IONS) incurs wider-than-expected Q2 loss. The company maintains its sales guidance for 2021 but expects to incur more losses.
Biotech Stock Roundup: BIIB's Q2 Earnings Update & Other Updates From AMGN, INCY
by Zacks Equity Research
The biotech sector was in focus last week on earnings results from Biogen (BIIB) and updates from Incyte (INCY) and others.
Drug/Biotech Stock Earnings on Jul 28: PFE, GSK, BMY, BMRN & TLRY
by Zacks Equity Research
Let us take a look at five drug/biotech companies - PFE, GSK, BMY, BMRN and TLRY - which are gearing up for their earnings release.
Biogen (BIIB) Q2 Earnings Top, Aduhelm Early Sales Hit $2M
by Zacks Equity Research
Biogen (BIIB) beats second-quarter estimates for both earnings and sales and ups sales guidance for 2021.
Biogen Inc. (BIIB) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 24.29% and 6.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on commercialization plans for new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports second-quarter earnings.
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $324.62 in the latest trading session, marking a -1.08% move from the prior day.
FibroGen (FGEN) Roxadustat Fails to Win FDA Advisory Panel Vote
by Zacks Equity Research
FibroGen (FGEN) is seeking approval for roxadustat as potential treatment of anemia of chronic kidney disease in the United States. Stock down on unfavorable advisory committee outcome.
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: BIIB & PRTA Provide Updates, CLDX Up on Positive Data & More
by Zacks Equity Research
The biotech sector was in focus last week on key updates form Biogen (BIIB) and Prothena (PRTA).
Ionis (IONS) Inks Deal With Bicycle Therapeutics for LICA Drugs
by Zacks Equity Research
Ionis (IONS) signs a deal with Bicycle Therapeutics to incorporate the latter's optimized Bicycle peptides into its LICA delivery platform.
Lilly (LLY) Stock Riding on Pipeline Developments This Year
by Zacks Equity Research
Lilly's (LLY) shares are up this year mainly due to positive developments related to its interesting pipeline of cancer, diabetes and Alzheimer's candidates.
Prothena (PRTA) to Sell ATTR Amyloidosis Program to Novo Nordisk
by Zacks Equity Research
Prothena (PRTA) announces an agreement to sell its clinical-stage antibody, PRX004, and the broader ATTR amyloidosis program for $1.2 billion to Novo Nordisk.
Biogen (BIIB) In-Licenses Rights to Multiple Sclerosis Drug
by Zacks Equity Research
Biogen partners with InnoCare Pharma for orelabrutinib, a BTK inhibitor with the potential of treating multiple sclerosis. The drug is currently undergoing phase II study.
Biogen (BIIB) Gets FDA Nod for Narrow Label of Aduhelm
by Zacks Equity Research
The FDA approves label update for Biogen's (BIIB) new Alzheimer's drug, Aduhelm. The updated label narrows the patient population, which is eligible for the drug.